Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin

We hypothesized that pazopanib is an inhibitor of cisplatin renal transporters OCT2, MATE1 and MATE2-K based on previous studies demonstrating an interaction between tyrosine kinase inhibitors and these transporters. Because several combinations of targeted therapies and cytotoxics are currently in development for cancer treatment, such an interaction is worth investigating. Experiments on HEK293 cells stably transfected to express OCT2, MATE1, MATE2-K or an empty vector (EV) were conducted. The inhibitory effect of pazopanib on these transporters was measured using the uptake of fluorescent substrate ASP+ and cisplatin in the different cell lines. The effect of pazopanib on cisplatin-induced cytotoxicity was also evaluated. A decrease of ASP+ uptake was observed in OCT2-HEK, MATE1-HEK and MATE2K-HEK cell lines after addition of pazopanib at increasing concentrations. Pazopanib inhibited cisplatin specific uptake in OCT2-HEK, MATE1-HEK and MATE2K-HEK lines. Cytotoxicity experiments showed that co-incubation of cisplatin with pazopanib multiplied up to 2.7, 2.4 and 1.6 times the EC50 values of cisplatin in OCT2-HEK, MATE1-HEK and MATE2K-HEK cell lines respectively, reaching about the same values as in EV-HEK cells. To conclude, pazopanib inhibits OCT2, MATE1 and MATE2-K, which are involved in cisplatin secretion into urine. The combination of these two drugs may lead to an interaction and increase the cisplatin-induced systemic toxicity. Given the wide variability of plasma pazopanib concentrations observed in vivo, the interaction may occur in a clinical setting, particularly in overexposed patients. The existence of a drug-drug interaction should be investigated when pazopanib is associated with a substrate of these transporters.

Pharmacological research. 2016 May 10 [Epub ahead of print]

C Sauzay, M White-Koning, I Hennebelle, T Deluche, C Delmas, D C Imbs, E Chatelut, F Thomas

Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France., Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059 France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe